Werner Koopman, theme Mitochondrial diseases, received 400,000 euro as a member of the PD-MitoQUANT consortium. The latter is an EU-funded Innovative Medicines Initiative research project that will improve our understanding of Parkinson’s so that better treatments can be developed in the future.The project will run for three years, receiving 4.5 million euro in funding from the EU’s Horizon 2020 programme and 2.46 million euro in-kind from European Federation of Pharmaceutical Industries and Associations (EFPIA) members and Parkinson’s UK.
PD-MitoQUANT focuses on how mitochondria, the ‘powerhouses’ of the cell, contribute to cell death and neurodegeneration when they malfunction. The project involves 14 partners from 9 countries, including academic experts from the Royal College of Surgeons in Ireland, Institut du Cerveau et de la Moelle Epinière, German Center for Neurodegenerative Diseases, Neuroscience Institute of the National Research Council, University College London, Radboud University Medical Centre, the Centre National de la Recherche Scientifique, SMEs (GeneXplain GmbH, Mimetas, Pintail Limited), pharmaceutical companies (Teva Pharmaceutical Industries Ltd.; H. Lundbeck A/S; UCB S.A.), and a patient advocacy organization (Parkinson’s UK).
Innovative Medicines Initiative (IMI): link.
Related news items
Protein supplementation improves lean body mass in physically active older adults21 March 2019
In the Journal of Cachexia, Sarcopenia & Muscle, Dominique ten Haaf and colleagues described a randomized clinical trial to assess the effects of 12-weeks protein supplementation on body characteristics.read more
eHealth Apps Replacing or Complementing Health Care Contacts21 March 2019
In the Journal of Medical Internet Research, Pim Assendelft and colleagues from the University of Applied sciences Arnhem Nijmegen showed that still relatively little is known about the adverse effects of health apps when used to replace or complement contacts with doctors or nurses.read more